论文部分内容阅读
目的分析四联疗法在幽门螺杆菌(Hp)感染患者中的应用效果。方法 98例Hp感染患者作为研究对象,采用随机数表法分为观察组与对照组,各49例。对照组给予三联疗法治疗,观察组给予四联疗法治疗。观察组两组Hp根除率以及不良反应情况。结果观察组Hp根除率为95.92%,高于对照组的79.59%,差异有统计学意义(χ~2=6.078,P<0.05)。两组治疗期间均未发生较为严重的不良反应。结论四联疗法的临床应用有利于改善Hp感染治疗效果,提升临床Hp根除率,故含铋剂四联疗法可作为临床治疗Hp感染的推荐方案,临床进一步普及价值高。
Objective To analyze the effect of quadruple therapy in patients with Helicobacter pylori (Hp) infection. Methods A total of 98 cases of Hp infection were selected as study subjects and divided into observation group and control group with 49 cases in each group. The control group received triple therapy, and the observation group received quadruple therapy. Observation group Hp eradication rate and adverse reactions. Results The eradication rate of Hp in observation group was 95.92%, which was higher than 79.59% in control group (χ ~ 2 = 6.078, P <0.05). No serious adverse reactions occurred during the two groups. Conclusion The clinical application of quadruple therapy is beneficial to improve the therapeutic effect of Hp infection and improve the clinical Hp eradication rate. Therefore, the bismuth-containing quadruple therapy can be used as the recommended treatment for Hp infection clinically, and its clinical value is further popularized.